Paul Ronald Bell
Director/Board Member chez BIOTA HOLDINGS LTD.
Profil
Paul Ronald Bell currently works at Biota Holdings Pty Ltd., as Independent Non-Executive Director from 2012 and Westmead Millennium Institute for Medical Research, as Director.
Mr. Bell also formerly worked at Cochlear Ltd., as Non-Executive Director from 2011 to 2014, Novozymes Biopharma AU Ltd., as Director from 2003 to 2006, Merck Sharp & Dohme (Australia) Pty Ltd., as Managing Director, Bio-Link Partners Ltd., as Director from 2005 to 2009, Aviragen Therapeutics, Inc., as Non-Executive Director from 2012 to 2013, Merck & Co., Inc., as President-Asia Pacific Human Health Division in 2002, and The Garvan Institute of Medical Research, as Member-Pharmaceutical Partnerships Program.
Mr. Bell received his graduate degree from the University of Canterbury.
Postes actifs de Paul Ronald Bell
| Sociétés | Poste | Début |
|---|---|---|
| BIOTA HOLDINGS LTD. | Director/Board Member | 28/07/2009 |
| Westmead Millennium Institute for Medical Research | Director/Board Member | - |
Anciens postes connus de Paul Ronald Bell
| Sociétés | Poste | Fin |
|---|---|---|
| COCHLEAR LIMITED | Director/Board Member | 14/10/2014 |
Aviragen Therapeutics, Inc.
 Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Director/Board Member | 01/05/2013 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2002 |
Novozymes Biopharma AU Ltd.
 Novozymes Biopharma AU Ltd. Pharmaceuticals: MajorHealth Technology Novozymes Biopharma AU Ltd. manufactures pharmaceuticals. The company is headquartered in Thebarton, Australia. | Director/Board Member | - |
Bio-Link Partners Ltd.
 Bio-Link Partners Ltd. Miscellaneous Commercial ServicesCommercial Services Bio-Link Partners Ltd. operates as a biotechnology business development company. The company is headquartered in Eveleigh, Australia. | Director/Board Member | - |
Formation de Paul Ronald Bell
| University of Canterbury | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| COCHLEAR LIMITED | Health Technology |
| Entreprise privées | 7 |
|---|---|
Biota Holdings Pty Ltd.
 Biota Holdings Pty Ltd. Pharmaceuticals: MajorHealth Technology Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia. | Health Technology |
Novozymes Biopharma AU Ltd.
Novozymes Biopharma AU Ltd. Pharmaceuticals: MajorHealth Technology Novozymes Biopharma AU Ltd. manufactures pharmaceuticals. The company is headquartered in Thebarton, Australia. | Health Technology |
The Garvan Institute of Medical Research
 The Garvan Institute of Medical Research Miscellaneous Commercial ServicesCommercial Services The Garvan Institute of Medical Research engages in the provision of biomedical research. It focuses in cancer, genomics and epigenetics, immunity and inflammation, healthy ageing, clinical trials, and research centres. The company was founded in 1963 and is headquartered in Darlinghurst, Australia. | Commercial Services |
Merck Sharp & Dohme (Australia) Pty Ltd.
 Merck Sharp & Dohme (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme (Australia) Pty Ltd. is an Australian research-intensive biopharmaceutical company committed to saving and improving lives. The private company is based in North Ryde, Australia and is dedicated to following the science to tackle some of the world's greatest health threats. MSD Australia has a long legacy of research in infectious disease and has been mobilizing its scientific expertise and experience to develop an effective response to the COVID-19 pandemic since it was first recognized. | Health Technology |
Bio-Link Partners Ltd.
Bio-Link Partners Ltd. Miscellaneous Commercial ServicesCommercial Services Bio-Link Partners Ltd. operates as a biotechnology business development company. The company is headquartered in Eveleigh, Australia. | Commercial Services |
| Westmead Millennium Institute for Medical Research | |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
